RYTM — Rhythm Pharmaceuticals Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syn… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$91.42
Market Cap$6.14B
Float55.7M
Shares Outstanding68.5M
Price/Sales (TTM)28.26
vs. Analyst Target+51.2% to analyst PT
Profit Margin-93.33%
Operating Margin (TTM)-87.11%
Revenue (TTM)$217M
Dividend RateNone
Analyst Target Price$138.20 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $35,000 -$131M -$690,000 -$136M
2021 $3.2M -$68.0M $2.6M -$169M
2022 $23.6M -$181M $21.5M -$174M
2023 $77.4M -$185M $68.1M -$168M
2024 $130M -$261M $117M -$238M
2025 $190M -$197M $170M -$174M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $48.5M -$46.6M
Sep 2025 $51.3M -$52.9M
Dec 2025 $57.3M -$47.5M
Mar 2026 $60.1M -$55.6M

Ownership & Float

Insider Ownership0.8%
Institutional Ownership110.0%
Short Float14.5%
% of All Funds Holding3.19%
Number of Funds Holding262

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$86.66Near-term / short-term trend
Weekly40-Week SMA$98.10Medium-term trend
Weekly80-Week SMA$81.21Cyclical trend (business cycle)
Weekly200-Week SMA$51.98Secular trend (multi-year)
Monthly10-Month SMA$98.90Near-term monthly trend
Monthly20-Month SMA$79.85Medium-term monthly trend
Monthly40-Month SMA$56.43Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$64.00 support 1.58x 9 months ago
$54.00 support 1.80x 12 months ago
$48.00 support 1.37x 17 months ago

Historical Earnings Reactions (35 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.60% -0.18% 40.00% 6.67% -9.50%
1 Day -0.07% -1.09% 45.71% 23.71% -16.54%
1 Week 0.93% 1.53% 54.29% 51.73% -44.05%
2 Weeks -0.10% 1.14% 54.29% 70.50% -48.61%
1 Month 4.02% 2.26% 55.88% 77.84% -44.86%

Next earnings: July 24, 2026 (57 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-5.2%33.3%9
Feb-4.9%33.3%9
Mar-5.7%11.1%9
Apr1.4%55.6%9
May-6.2%25.0%8
Jun4.7%50.0%8
Jul28.2%50.0%8
Aug23.9%75.0%8
Sep-4.1%37.5%8
Oct-1.5%37.5%8
Nov13.7%77.8%9
Dec4.1%55.6%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.28% 53.1% 405
Tuesday 0.27% 52.2% 448
Wednesday 0.39% 51.2% 443
Thursday -0.20% 45.7% 435
Friday 0.05% 48.6% 436

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 110.0%

Insider Transactions — Smart Summary

Total insider ownership: 0.8%

12-Month Insider Activity Summary

Total Filings27
Net Value-$21.8M
Net Shares Change-23,204
% of Float-0.0%
C-Suite Filings26
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
Shulman Joseph Chief Technical Officer -$2.4M 2 N/A
Smith Hunter C Chief Financial Officer -$2.2M 3 N/A
Cramer Pamela J. Chief Human Resources Officer -$2.1M 2 N/A
German Christopher Paul Corporate Controller and CAO -$716,652.949 2 2 sell
Garfield Alastair Chief Scientific Officer -$85,483.071 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-06-03 – 2025-06-12 5 5 -$8.4M 4 C-suite
2025-07-03 – 2025-07-11 5 5 -$5.0M 5 C-suite
2025-08-13 – 2025-08-25 4 3 -$3.2M 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-19 German Christopher Paul Corporate Controller and CAO -$240,818.109 Transaction at $67.19, now +36.1%
2026-03-06 German Christopher Paul Corporate Controller and CAO -$475,834.84 Transaction at $53.77, now +70.0%
2025-07-03 Garfield Alastair Chief Scientific Officer -$85,483.071 Transaction at $64.81, now +41.1%
2026-02-19 Smith Hunter C Chief Financial Officer -$805,813.377 Transaction at $101.31, now -9.8%
2026-02-12 Smith Hunter C Chief Financial Officer -$708,575.718 Transaction at $100.21, now -8.8%
2026-02-06 Smith Hunter C Chief Financial Officer -$702,744.305 Transaction at $106.03, now -13.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Rhythm Pharmaceuticals Inc (RYTM) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for RYTM on Trend Edge →